| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formula Iwherein Arepresents CR; Arepresents CRor N; Rand Rare independently specified in hydrogen, halogen, and halogen-C-alkyl; Rand Rare independently specified in hydrogen, C-alkyl, halogen, halogen-C-alkyl and C-alkoxy; Ris specified in hydrogen, C-alkyl, halogen, C-alkoxy, piperidinyl and -NRR, wherein Rand Rare independently specified in hydrogen, C-alkyl and C-cycloalkyl; Ris specified in hydrogen and C-alkyl; or Rand Ror Rand Rtogether represent -X-(CRR)- and form a part of the ring, wherein X is specified in -CRR- and -NR-; R, R, R, Rare hydrogen; Ris specified in hydrogen, C-alkyl, C-cycloalkyl or C-cycloalkyl-C-alkyl, wherein C-cycloalkyl is substituted or not by C-alkoxycarbonyl, and C-alkylsulphonyl; and n represents 1, 2 or 3; Brepresents N or N-O; Brepresents CRor N; R, Rand Rare independently specified in hydrogen, halogen and C-alkyl; and R, R, R, Rand Rare those as presented in the patent claim. The compound also refers to pharmaceutically acceptable salts of the compounds of formula I and to pharmaceutical compositions possessing GPBAR1 receptor agonist activity.EFFECT: compounds of formula I as GPBAR1 agonists.20 cl, 85 ex |
